Why do we need new and better antidepressants?
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The range of available antidepressants is reviewed in relation to mechanisms of action and the evidence of efficacy in general and efficacy in severe depression in particular. In studies investigating efficacy in major depressive disorder, not all antidepressants have been shown to have clear-cut efficacy in severe depression. Here, the minimum standards for the necessary methodology to investigate efficacy in severe depression are reviewed and the methods that are needed to establish efficacy as a superior antidepressant or as an antidepressant with a faster than expected response are suggested. A review of the mechanisms of action of different antidepressants is accompanied by a critical review of the properties of an antidepressant likely to achieve either efficacy in severe depression or the status of a superior antidepressant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130 · cited 1×
“It has been shown that those suffering from depression, as well as having reduced social and work function, also have reduced physical function, poorer current health and more pain compared to individuals without a chronic condition (Wells et al., 1989).”
BackgroundMortality of patients with mood disorders: follow-up over 34–38 years
Angst, F., Stassen, H. H., Clayton, P. J., & Angst, J. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00377-9 · Cited by 881 · cited 3×
“2 in a meta-analysis of eight studies of patients suffering from depression, and more recent studies in a wider depressed population have reported similar figures (Angst et al., 2002).”
BackgroundResultInfluentialKeller, M. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100053010 · Cited by 864
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 2×
“, 2004) and duloxetine (Arnold et al., 2004) have been shown to be effective compared with placebo in syndromes of pain (e.”
BackgroundSelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209 · cited 3×
“A review of the data suggested that the symptoms occurred whether the antidepressant was discontinued gradually or abruptly (Lejoyeux et al., 1996; Therrien and Markowitz, 1997; Zajecka et al., 1998) and that there might be a difference in the rate of occurrence with different SSRIs (Price et al.”
BackgroundThe treatment of depression: prescribing patterns of antidepressants in primary care in the UK
Donoghue, J. M., & Tylee, A. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.2.164 · Cited by 209
WELLS, J. E., & HORWOOD, L. J. (2004) · Psychological Medicine · doi:10.1017/s0033291703001843 · Cited by 199
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Self-citationMiller, H. L. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020031005 · Cited by 192 · cited 1×
“A series of depletion studies to test the functional integrity of the serotonin system or catecholamine system (Delgado et al., 1990; Miller et al., 1998) found that depletion of the serotonin system produced a sharp return of depressive symptoms mainly in those patients who had responded to…”
Background
Cited by
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338
Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139
Möller, H.-J. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802264606 · Cited by 107
Fornaro, M., McCarthy, M. J., De Berardis, D., Pasquale, D., Martino, Colicchio, Cattaneo, D'Angelo, Fornaro, P., & Tabaton (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41557 · Cited by 67
“9,51,76,77 It will be of interest in the future to determine whether agomelatine affects excessive or atypical eating behaviors in the context of depression, especially in the view that animal studies have reported that 5-HT2B agonists concur with hyperphagia and reduce grooming in rodents, 78…”
Florea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B., & Abetz-Webb, L. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.008 · Cited by 35
Metadata
- Authors
- Montgomery, S. A.
- Venue
- International Clinical Psychopharmacology
- Published
- 2006-02
- Volume
- 21
- Issue
- Supplement 1
- Pages
- S1-S10
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2047265855
- Cited by
- 59
- References
- 18
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why do we need new and better antidepressants? https://app.cochat.ai/papers/10.1097/01.yic.0000199455.39552.1c
- The paper
- Montgomery, S. A. (2006). Why do we need new and better antidepressants? International Clinical Psychopharmacology. https://doi.org/10.1097/01.yic.0000199455.39552.1c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.